Personalized stem cell transplant aims to beat inherited blood cancers
NCT ID NCT07524530
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 35 times
Summary
This study tests whether adjusting chemotherapy doses for each patient can improve outcomes after a stem cell transplant for blood cancers caused by a RUNX1 gene mutation. Up to 98 people aged 4 to 70 with these cancers will receive a transplant from a half-matched donor. The goal is to see if this personalized approach leads to better disease-free survival at one year compared to past results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stem cell transplant with chemotherapy drugs (cyclophosphamide, busulfan, fludarabine)
- What this could lead to
- If successful, this could show that personalized chemotherapy doses improve survival after stem cell transplant for people with RUNX1-related blood cancers.
- What could go wrong
- This is a Phase II trial with only 98 participants, so results may not apply to everyone. Stem cell transplants carry serious risks like infection and graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORE BINDING FACTOR ALPHA SUBUNITS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A simple blood test may reveal hidden infertility risk in young cancer survivors